{"version":"1.0","type":"link","title":"Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review).","author_name":"Du J 외","author_url":"https://prs-insight.online/author/Du%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/84891","thumbnail_width":1200,"thumbnail_height":630}